首页> 外国专利> NOVEL MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY

NOVEL MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY

机译:调节NMDA受体介导的毒性的新颖意味着

摘要

The present invention relates to the field of neurodegenerative processes and means to provide protection against the same. In particular, the present invention relates to polypeptides, fusion proteins, and other compounds interacting with the N-terminal domain of transient receptor potential melastatin subfamily member 4 (TRPM4), which are capable of interfering with NMDA receptor mediated neurotoxicity. The present invention also relates to nucleic acids encoding the aforementioned polypeptides or fusion proteins, compositions comprising the same and the use of said polypeptides, fusion proteins, and other compounds in methods for treating or preventing a disease of the human or animal body, for example in a method of treating diseases like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) or stroke.
机译:本发明涉及神经变性工艺领域和提供保护的方法。 特别地,本发明涉及多肽,融合蛋白和与瞬态受体潜在素母苷蛋白酶4(TRPM4)的N-末端结构域相互作用的其他化合物,其能够干扰NMDA受体介导的神经毒性。 本发明还涉及编码上述多肽或融合蛋白的核酸,其包含相同和使用所述多肽,融合蛋白和其他化合物的组合物,例如用于治疗或预防人体或动物体疾病的方法中的方法 在一种治疗阿尔茨海默病(AD)等疾病的方法中,肌营养的外侧硬化症(ALS),亨廷顿的疾病(HD)或中风。

著录项

  • 公开/公告号EP3867267A1

    专利类型

  • 公开/公告日2021-08-25

    原文格式PDF

  • 申请/专利权人 FUNDAMENTAL PHARMA GMBH;

    申请/专利号EP20190786817

  • 发明设计人 BADING HILMAR;YAN JING;

    申请日2019-10-18

  • 分类号C07K14/705;C07K16/28;C12N15/113;C07D401/12;

  • 国家 EP

  • 入库时间 2022-08-24 20:46:46

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号